Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The holiday season is right around the corner, and as the Canadian consumer looks to open up their wallet in one of the biggest seasons for retail, the so-called Santa Claus rally may have one just bump to give the stock market before the page turns on a new year. Indeed, it’s been a great year to be a stock investor. And while the year’s gains seem less likely to be topped come the new year, I think there are intriguing options out there that may not be nearly as bid up as the market, specifically the S&P 500, which I view as getting expensive, especially compared to the TSX Index. Indeed, just because the markets as a whole are expensive does not mean that there aren’t undervalued names lurking under the radar. Indeed, some of the best value bets may actually be large-cap names hiding in plain sight. And in this piece, we’ll check out two such names that are not at all overheated and are potentially extremely undervalued. So, if you’re searching for relative value in a hot market, the following names may be worth stashing on your December shopping list! Quebecor First, we have a Quebec-based telecom firm, ( ), which is also now the proud owner of discount wireless carrier Freedom Mobile. Indeed, Freedom Mobile may be best known as a carrier that offers competitive prices. However, it still has a way to go on the network quality front if it’s to really disrupt the Big Three telecom titans as they duke it out for the national wireless crown. In short, Quebecor is an underdog but one that I think is worth betting on as the firm looks to take on national behemoths that are magnitudes larger than its size (Quebecor is a mere $7.48 billion company). As Freedom continues investing in its 5G network, I think that more Canadians may gravitate towards the offering in a bid to save a few bucks per month. Indeed, inflation may have been tamed, but the for solid value propositions has not faded—not in the slightest. With a ridiculously low 10.3 times trailing price to earnings (P/E) and a nice 4.04% dividend yield, I’d look at the stock closely after its latest November correction, one that I think is overdone. Coca-Cola Speaking of corrections, ( ) stock is still just nearly 13% from its all-time high. Indeed, there’s a pretty strong level of support in the $62-63 range, making the recent dip seem like an opportunistic entry point. The stock boasts a nice 3.04% dividend yield and goes for 26.5 times trailing P/E. Indeed, that’s a modest dividend for a rather expensive price. While Coca-Cola’s controversial artificial intelligence (AI) advertisements may not hit the spot for many (I must say that I was not a big fan of the holiday ad), I see many areas where the firm can grow and move on from its recent pullback. Perhaps new products and targeted ads may be able to bring back some of the fizz to KO shares. Either way, you’re getting a legendary consumer staple that’s worth venturing south of the border for while it’s still down. As long as Coke pulls back on the AI ads, I think its marketing campaign can hit the ground running again.7 AI Automation Trends You Can’t Ignore in 2025
Thankful Investors - Last 5 YearsNone
Frankly Speaking: Will President Trump be able to end the wars in Gaza and Ukraine?
LAS VEGAS, Nov 23 (Reuters) - Formula One leader Max Verstappen said he was surprised to be ahead of title challenger Lando Norris after qualifying fifth for the Las Vegas Grand Prix despite a rear wing disadvantage. Verstappen's Red Bull has been slower on the Las Vegas straights than his rivals, with the team explaining they had not designed a special low downforce rear wing for cost reasons. The Dutchman can capture his fourth successive Formula One championship on Saturday if he beats McLaren's Norris, who was sixth in qualifying. "We tried to do the best we could," Verstappen told reporters after qualifying, where Mercedes driver George Russell took the pole. "We worked well together. We tried a lot of different things to see what was the right direction... still clearly not enough to fight for pole. I'm still quite happy. "We are still in front of McLaren, which for me is a bit of a surprise but I'm quite happy with how qualifying went and my laps." Verstappen, 62 points clear of Norris with 60 remaining to be won after Las Vegas, downplayed expectations that he would clinch the title on Saturday at the race he won in its first iteration last year. "At the moment, it's difficult to tell," he said. "Both of us were not great on the long run, we both (degraded) on the tyres compared to other teams. "But a lot of teams have made changes, so only time will tell tomorrow how we will perform." Norris said Mercedes and Ferrari have both shown the superiority of their cars in Las Vegas and that he was not comfortable pushing too hard. "When you are trying to find lap time but not go over the limit it's a difficult balance," he said. "So just too much of a challenge for us and that showed." The Briton said beating Verstappen to extend the battle for the championship to Qatar was his focus. "I'll do everything I can, of course. That's what I'm here to do," he said. "I'm not going to give up until the end even if the chance is extremely thin. "But I'm here to do the best in every race I can whether I'm fighting for a championship or not. "So I'll go out tomorrow, it's a long race, many things can happen. We're quick in the straight so hopefully that can come to our advantage." Sign up here. Reporting by Rory Carroll in Las Vegas, Additional reporting by Alan Baldwin, editing by Ed Osmond Our Standards: The Thomson Reuters Trust Principles. , opens new tab Thomson Reuters Los Angeles-based sports reporter who interviews the most impactful athletes and executives in the world. Covers breaking news ranging from the highs of championship victories to the lows of abuse scandals. My work highlights the ways in which sports and the issues of race, gender, culture, finance, and technology intersect.